Literature DB >> 35373070

Worsening Kidney Function, Proteinuria, and Hematuria in a Patient with CLL.

Pavan Chopra1, Nicole K Andeen1, Stephen E Spurgeon1,2.   

Abstract

Entities:  

Keywords:  chronic lymphocytic leukemia; clinical nephrology; hematuria; proteinuria

Mesh：

Year:  2021        PMID： 35373070      PMCID： PMC8791335          DOI： 10.34067/KID.0003452020

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  5 in total

1.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

2.  Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.

Authors:  John C Byrd; Joseph M Flynn; Thomas J Kipps; Michael Boxer; Kathryn S Kolibaba; David J Carlile; Guenter Fingerle-Rowson; Nicola Tyson; Jamie Hirata; Jeff P Sharman
Journal:  Blood       Date:  2015-10-15       Impact factor: 22.113

Review 3.  Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.

Authors:  Arpita Shah
Journal:  Ann Pharmacother       Date:  2014-07-18       Impact factor: 3.154

4.  Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab.

Authors:  Punit Jain; Rashmi Kanagal-Shamanna; William Wierda; Alessandra Ferrajoli; Michael Keating; Nitin Jain
Journal:  Hematol Oncol Stem Cell Ther       Date:  2016-06-23

Review 5.  Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Authors:  Brian T Hill; Matt Kalaycio
Journal:  Onco Targets Ther       Date:  2015-08-31       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.